特应性皮炎系统免疫调节治疗:活系统评价与网络Meta分析更新
结果显示,在成人最多16周治疗中,来金珠单抗与度普利尤单抗在EASI、POEM、DLQI和PP-NRS变化上无重要差异,但度普利尤单抗在二分疗效结局中胜算更高;高剂量乌帕替尼和阿布昔替尼相对疗效数值最高。安全性因事件率低限制比较。
要点
- 来金珠单抗短期疗效与度普利尤单抗相当,但度普利尤单抗二分疗效结局更优。
- 高剂量乌帕替尼和阿布昔替尼相对疗效数值最高。
- 安全性事件率低,限制系统治疗间有用比较。
核心结论
- 在成人特应性皮炎短期治疗中,来金珠单抗与度普利尤单抗疗效相似。
- 临床医生和患者可利用这些比较数据辅助治疗决策。
研究设计与样本
- 评估至少8周系统免疫调节药物治疗,采用随机效应贝叶斯网络Meta分析。
主要发现
- 来金珠单抗对比度普利尤单抗:EASI变化MD -2.0(95%CrI -4.5至0.3;中等确定性)。
- 来金珠单抗对比度普利尤单抗:POEM变化MD -1.1(95%CrI -2.5至0.2;中等确定性)。
- 来金珠单抗对比度普利尤单抗:DLQI变化MD -0.2(95%CrI -2.1至1.6;中等确定性)。
- 来金珠单抗对比度普利尤单抗:PP-NRS变化MD 0.1(95%CrI -0.4至0.6;高确定性)。
- 度普利尤单抗在二分疗效结局中相比来金珠单抗具有更高胜算。
关键数值与推荐
- 其他获批系统药物相对疗效与既往更新相似,高剂量乌帕替尼和阿布昔替尼数值最高。
- 安全性结局事件率低,限制有用比较。
临床怎么用
- 来金珠单抗可作为与度普利尤单抗短期疗效相似的选项。
- 选择系统治疗时需结合二分疗效结局和安全性数据个体化决策。
局限性
- 安全性事件率低限制系统治疗间比较。
- 来金珠单抗对比数据主要限于成人最多16周治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are multiple approved systemic treatments for atopic dermatitis. Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in clinical trials but not to other systemic treatments. OBJECTIVE: To compare reported measures of efficacy and safety of lebrikizumab to other systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis. DATA SOURCES: The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Latin American and Caribbean Health Science Information database, the Global Resource of Eczema Trials database, and trial registries were searched from inception through November 3, 2023. STUDY SELECTION: Randomized clinical trials evaluating 8 or more weeks of treatment with systemic immunomodulatory medications for moderate to severe atopic dermatitis. Titles, abstracts, and full texts were screened in duplicate. DATA EXTRACTION AND SYNTHESIS: Data were abstracted in duplicate and random-effects bayesian network meta-analyses were performed. Minimal important differences were used to define important differences between medications. Certainty of evidence was assessed using the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation). The updated analysis was completed from December 13, 2023, to February 20, 2024. MAIN OUTCOME MEASURES: Efficacy outcomes were the Eczema Area and Severity Index (EASI), the Patient Oriented Eczema Measure (POEM) Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS) and were compared using mean difference (MD) with 95% credible intervals (CrI). Safety outcomes were serious adverse events and withdrawal due to adverse events. Other outcomes included the proportion of participants with 50%, 75%, and 90% improvement in EASI (EASI-50, -75, -90) and the proportion with success on the Investigator Global Assessment compared using odds ratios with 95% CrI. RESULTS: The study sample included 97 eligible trials, with a total of 24 679 patients. Lebrikizumab was associated with no important difference in change in EASI (MD, -2.0; 95% CrI, -4.5 to 0.3; moderate certainty), POEM (MD, -1.1; 95% CrI -2.5 to 0.2; moderate certainty), DLQI (MD, -0.2; 95% CrI -2.1 to 1.6; moderate certainty), or PP-NRS (MD, 0.1; 95% CrI -0.4, 0.6; high certainty) compared to dupilumab among adults with atopic dermatitis who were treated for up to 16 weeks. Dupilumab was associated with higher odds of efficacy in binary outcomes compared with lebrikizumab. The relative efficacy of other approved systemic medications was similar to that found by previous updates of this living study, with high-dose upadacitinib and abrocitinib demonstrating numerically highest relative efficacy. For safety outcomes, low event rates limited useful comparisons. CONCLUSIONS AND RELEVANCE: In this living systematic review and network meta-analysis, lebrikizumab was similarly effective to dupilumab for the short-term treatment of atopic dermatitis in adults. Clinicians and patients can use these comparative data to inform treatment decisions.
引用
- Drucker AM, Lam M, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. JAMA Dermatol. 2024. PMID: 39018058. doi:10.1001/jamadermatol.2024.2192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。